Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
OncoSil Medical LtdTelephone
61.2.8935.9629
Address
Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113
Description
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$10,747.00
1 week
0%
1 month
-42.86%
YTD
-5.88%
1 year
5.88%
All time high
0.20
EPS 3 yr Growth
-44.30%
EBITDA Margin
%
Operating Cashflow
-$11m
Free Cash Flow Return
-147.50%
ROIC
-162.30%
Interest Coverage
-3,293.30
Quick Ratio
3.30
Shares on Issue (Fully Dilluted)
2539m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
06 November 24 |
Prospectus 2024 Share Purchase Plan (SPP) Offer
×
Prospectus 2024 Share Purchase Plan (SPP) Offer |
05 November 24 |
Change in substantial holding from PCG
×
Change in substantial holding from PCG |
01 November 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
01 November 24 |
Notice under section 708A
×
Notice under section 708A |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 October 24 |
Amended Share Purchase Plan (SPP) Timetable
×
Amended Share Purchase Plan (SPP) Timetable |
29 October 24 |
OncoSil Appoints Rachel Duggan as EMEA Sales Director
×
OncoSil Appoints Rachel Duggan as EMEA Sales Director |
29 October 24 |
Update - Proposed issue of securities - OSL
×
Update - Proposed issue of securities - OSL |
28 October 24 |
OSL completes $7 M Placement and announces $1 M SPP
×
OSL completes $7 M Placement and announces $1 M SPP |
28 October 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
28 October 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
28 October 24 |
Capital Raise Presentation
×
Capital Raise Presentation |
28 October 24 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
24 October 24 |
Trading Halt
×
Trading Halt |
24 October 24 |
G-BA Approval received for OncoSil Device
×
G-BA Approval received for OncoSil Device |
22 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
21 October 24 |
OncoSil Medical Limited Receives UKCA Renewal Certificates
×
OncoSil Medical Limited Receives UKCA Renewal Certificates |
07 October 24 |
OncoSil signs distribution agreement with Al Zahrawi Medical
×
OncoSil signs distribution agreement with Al Zahrawi Medical |
02 October 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
30 September 24 |
Peter Hall elects not to join OncoSil Board
×
Peter Hall elects not to join OncoSil Board |
30 September 24 |
Annual Report
×
Annual Report |
30 September 24 |
Annual Report Differences to Appendix 4E
×
Annual Report Differences to Appendix 4E |
30 September 24 |
Corporate Governance Statement and Appendix 4G
×
Corporate Governance Statement and Appendix 4G |
26 September 24 |
50% Recruitment in TRIPP-FFX and PANCOSIL Clinical Trials
×
50% Recruitment in TRIPP-FFX and PANCOSIL Clinical Trials |
18 September 24 |
Comparative Analysis Indicates Benefits from OncoSil
×
Comparative Analysis Indicates Benefits from OncoSil |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.